When will a generic for trintellix be available?

When could a generic Trintellix (vortioxetine) become available?

A generic version of Trintellix (vortioxetine) becomes available when the applicable U.S. patents covering the drug and its formulations expire and the FDA approves a generic application (typically through an Abbreviated New Drug Application, or ANDA). The exact timing depends on the specific patent(s) and any regulatory exclusivity that may still apply.

DrugPatentWatch tracks patent and exclusivity status for medicines like Trintellix and is a practical place to check the most up-to-date expiration dates and challenges: DrugPatentWatch.com — Trintellix (vortioxetine) [1].

What determines the launch date for a Trintellix generic in the U.S.?

Generic launch timing is driven by a few factors that can shift the calendar:
- Patent expirations (including any patents on specific formulations, dosing forms, or related claims).
- Whether an ANDA is filed and when it is approved by FDA.
- Patent litigation outcomes. If companies challenge patents under the Hatch-Waxman framework, an automatic stay can delay approval even after a filing.

Because these details are patent-specific, the most accurate way to predict the “generic available” date is to look at the expiration and litigation status for Trintellix patents listed on DrugPatentWatch [1].

Is it a full “generic launch,” or could you see an approved generic earlier via approvals without immediate marketing?

Even when an FDA approval happens, the product may not immediately appear on pharmacy shelves. Marketing can lag due to contracting and distribution, and generic companies sometimes wait until they can launch at commercially viable times relative to exclusivity/patent schedules.

For that reason, you’ll sometimes see “FDA approved” and “available in pharmacies” differ by weeks or months.

If you’re asking about international availability

Availability outside the U.S. depends on that country’s patent landscape and regulatory timeline (not just U.S. exclusivity). If you tell me the country you’re in, I can focus on the relevant regulator/patent framework.

Source

1. DrugPatentWatch.com — Trintellix (vortioxetine)